Wang Liangfang, Liang Chang, Chen Pingrun, Cao Yubin, Zhang Yan
Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, PR China.
West China School of Medicine, Sichuan University, Chengdu, PR China.
Therap Adv Gastroenterol. 2023 Mar 6;16:17562848231155022. doi: 10.1177/17562848231155022. eCollection 2023.
Patients with inflammatory bowel disease (IBD) are often accompanied by a more significant burden of depression or anxiety, and approximately one-third are prescribed antidepressants. However, previous studies on the efficacy of antidepressants in IBD have shown inconsistent results.
To evaluate the effect of antidepressants on depression, anxiety, disease activity, and quality of life (QoL) in IBD patients.
A systematic review and meta-analysis.
We searched MEDLINE Ovid, EMBASE Ovid, the Cochrane Library, CINAHL, PsycINFO, Chinese CBM Database, China National Knowledge Infrastructure, VIP, and Wanfang Database from inception to 13th July 2022 without language restrictions.
In all, 13 studies containing 884 individuals were included. Compared with the control group, antidepressants were superior in reducing depression scores [standardized mean difference (SMD) = -0.791; 95% confidence interval (CI): -1.009 to -0.572; < 0.001], anxiety scores (SMD = -0.877; 95% CI: -1.203 to -0.552; < 0.001), and disease activity scores (SMD = -0.323; 95% CI: -0.500 to -0.145; < 0.001). Antidepressants had a positive effect in reaching clinical remission [risk ratio (RR) = 1.383; 95% CI: 1.176-1.626; < 0.001]. Higher physical QoL (SMD = 0.578; 95% CI: 0.025-1.130; = 0.040), social QoL (SMD = 0.626; 95% CI: 0.073-1.180; = 0.027), and Inflammatory Bowel Disease Questionnaire (SMD = 1.111; 95% CI: 0.710-1.512; < 0.001) were found in the experimental group. No significant differences were observed in clinical response (RR = 1.014; 95% CI: 0.847-1.214; = 0.881), psychological QoL (SMD = 0.399; 95% CI: -0.147 to 0.944; = 0.152), and environmental QoL (SMD = 0.211; 95% CI: -0.331 to 0.753; = 0.446).
Antidepressants are effective for ameliorating depression, anxiety, disease activity, and QoL in IBD patients. Due to most studies having a small sample size, further well-designed studies are required.
炎症性肠病(IBD)患者常伴有更严重的抑郁或焦虑负担,约三分之一的患者会使用抗抑郁药。然而,先前关于抗抑郁药在IBD中疗效的研究结果并不一致。
评估抗抑郁药对IBD患者抑郁、焦虑、疾病活动及生活质量(QoL)的影响。
系统评价与荟萃分析。
检索MEDLINE(Ovid)、EMBASE(Ovid)、Cochrane图书馆、CINAHL、PsycINFO、中国生物医学文献数据库、中国知网、维普和万方数据库,检索时间从建库至2022年7月13日,无语言限制。
共纳入13项研究,涉及884例个体。与对照组相比,抗抑郁药在降低抑郁评分[标准化均数差(SMD)=-0.791;95%置信区间(CI):-1.009至-0.572;P<0.001]、焦虑评分(SMD=-0.877;95%CI:-1.203至-0.552;P<0.001)和疾病活动评分(SMD=-0.323;95%CI:-0.500至-0.145;P<0.001)方面更具优势。抗抑郁药在实现临床缓解方面有积极作用[风险比(RR)=1.383;95%CI:1.176 - 1.626;P<0.001]。在实验组中发现更高的身体生活质量(SMD=0.578;95%CI:0.025至1.130;P=0.040)、社会生活质量(SMD=0.626;95%CI:0.073至1.180;P=0.027)和炎症性肠病问卷评分(SMD=1.111;95%CI:0.710至1.512;P<0.001)。在临床反应(RR=1.014;95%CI:0.847至1.214;P=0.881)、心理生活质量(SMD=0.399;95%CI:-0.147至0.944;P=0.152)和环境生活质量(SMD=0.211;95%CI:-0.331至0.753;P=0.446)方面未观察到显著差异。
抗抑郁药对改善IBD患者的抑郁症状、焦虑、疾病活动及生活质量有效。由于大多数研究样本量较小,需要进一步开展设计良好的研究。